Loading stock data…
$3.28-0.11 (-3.24%)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Clene Inc. in the Consumer Defensive sector is trading at $3.28 with a market capitalization of $57M. Wall Street consensus targets $32.20 (5 analysts), implying a +881.7% move over the next 12 months. The stock is currently near its 52-week low of $3.25, remaining 38.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $90,000↑ | $15,000↓ | $77,000↑ | $15,000↓ | $27,000 |
| Gross Profit | $54,000↑ | $15,000↓ | $54,000↑ | $15,000↓ | $27,000 |
| Operating Income | -$5.16M↓ | -$1.69M↑ | -$7.24M↓ | -$5.37M↑ | -$5.63M |
| Net Income | -$13.42M↓ | -$8.09M↑ | -$9.23M↓ | -$8.78M↓ | -$7.42M |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in vario...